| The effects of a binary mixture of benzo(a)pyrene and 7H-dibenzo(c,g)carbazole on lung tumors and K-ras oncogene mutations in strain A/J mice. | lung, |
| Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. | lung, |
| Epithelial proliferation and ras p21 oncoprotein expression in rectal mucosa of patients with ulcerative colitis. | colorectal, |
| Prognostic significance of DNA aneuploidy and p21 ras oncoprotein expression in colorectal cancer and their role in the determination of treatment modalities. | colorectal, |
| Ki-ras proto-oncogene mutations in sporadic colorectal adenomas: relationship to histologic and clinical characteristics. | colorectal, |
| Oncogenic potential of c-erbB-2 and its association with c-K-ras in premalignant and malignant lesions of the human uterine endometrium. | uterine, |
| Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. | lung, |
| Possible role of K-ras oncogene in mutagenic activity of ethylnitrosourea on lymphocyte hyperproliferation in rat colon. | colorectal, |
| Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. | lung, |
| CCAAT/enhancer binding protein-beta is a mediator ofkeratinocyte survival and skin tumorigenesis involving oncogenic Ras signaling. | skin, |
| We report here that C/EBPbeta-nullizygous mice are completely refractory to skin tumor development induced by a variety of carcinogens that produce tumors containing oncogenic Ras mutations. | skin, |
| [Detection of K-ras and p-53 oncogene mutations in a patient with acute lymphoblastic leukemia before and after bone marrow transplantation]. | leukemia, |
| Detection of genetic alterations in the p53 suppressor gene and the K-ras oncogene among different grades of dysplasia in patients with colorectal adenomas. | colorectal, |
| [Point mutations of N-ras oncogene and abnormal expression of rasp21, p53 proteins in orbital rhabdomyosarcoma]. | sarcoma, |
| Use of spontaneous Epstein-Barr virus-lymphoblastoid cell lines genetically modified to express tumor antigen as cancer vaccines: mutated p21 ras oncogene in pancreatic carcinoma as a model. | pancreatic, |
| K-ras mutations and RASSF1A promoter methylation in colorectal cancer. | colorectal, |
| Concurrent mutations of K-ras oncogene at codons 12 and 22 in colon cancer. | colorectal, |
| Association between the ras p21 oncoprotein in blood samples and breast cancer. | breast, |
| Inhibition of oncogenic K-ras signaling by aerosolized gene delivery in a mouse model of human lung cancer. | liver,lung, |
| Mutant K-ras oncogene regulates steroidogenesis of normal human adrenocortical cells by the RAF-MEK-MAPK pathway. | adrenocortical, |